Process Validation(PV)
Documented evidence that a process consistently produces a product meeting predetermined specifications and quality attributes.
Usage Examples
- Process validation included three PPQ batches.
- CPV data showed the process remained in control.
- Validation demonstrated consistent tablet hardness.
What is PV?
Process Validation is the collection and evaluation of data that establishes scientific evidence that a process is capable of consistently delivering quality product. The FDA guidance (2011) describes a lifecycle approach with three stages.
Stage 1 (Process Design): Establish commercial process based on development and scale-up. Stage 2 (Process Qualification): Confirm process design through prospective validation batches. Stage 3 (Continued Process Verification): Ongoing monitoring during routine production.
Traditional validation required three consecutive successful batches. Modern approaches emphasize understanding process variability and may use statistical methods to determine appropriate batch numbers.
Regulatory Context
This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 211, FDA PROCESS VALIDATION GUIDANCE, ICH Q8.
When This Matters
- Process validation included three PPQ batches.
- CPV data showed the process remained in control.
- Validation demonstrated consistent tablet hardness.
Common Mistakes
- Failing to align CMC change narratives with current CFR/ICH expectations.
- Submitting incomplete control strategy documentation.
- Separating manufacturing and regulatory review cycles too late in execution.
Related Regulations
How to Execute FDA 3-Stage Process Validation
Validate a pharmaceutical manufacturing process per FDA's 2011 Process Validation guidance through process design, qualification, and continued process verification.
- 1
Stage 1 — Process Design
Establish process knowledge during development. Identify Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), and their relationships through DoE. Build the control strategy. Document in development reports and transfer package.
- 2
Define PPQ protocol
Write the Process Performance Qualification (PPQ) protocol specifying: number of batches (typically 3), critical parameters to monitor, acceptance criteria, sampling plan, analytical methods, and statistical evaluation approach. Protocol is pre-approved by Quality.
- 3
Qualify facilities, utilities, equipment
Complete IQ/OQ/PQ for all GMP facilities, utilities (water, HVAC, compressed air), and process equipment before PPQ. Cleaning validation for shared equipment. Analytical method validation per ICH Q2(R1).
- 4
Stage 2 — Execute PPQ batches
Manufacture the specified number of consecutive PPQ batches (typically 3) within the defined operating ranges. Comprehensive sampling at all critical steps. All in-process and finished product testing per the validation protocol.
- 5
Evaluate PPQ data
Statistical analysis of PPQ results against acceptance criteria. Evaluate batch-to-batch reproducibility, process capability (Cpk), and attribute consistency. Pass criteria typically include zero critical deviations and all attributes within release specifications.
- 6
File validation report
PPQ report summarizing execution, results, deviations (and investigation), and conclusion. QA approval of the report triggers release for commercial manufacture. Validation summary appears in CTD Module 3.2.P.3.5.
- 7
Stage 3 — Continued Process Verification
Ongoing monitoring of process performance during routine commercial manufacture. Statistical trending of CPPs and CQAs, periodic process capability assessment, and investigation of shifts or trends. Lifecycle feedback into process improvement and control strategy updates.
Frequently Asked Questions
The FDA lifecycle approach doesn't mandate exactly three batches. The number should be justified based on process understanding, variability, and statistical confidence required.
Significant changes to equipment, process parameters, raw materials, manufacturing site, or scale may require revalidation. The extent depends on risk assessment of the change.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Track ICH quality guidelines automatically and get alerts when changes impact your products
Track GxP regulation changes and enforcement trends
Related Regulatory Intelligence
Related Actions
Sources & References

